Oncolin Therapeutics Announces the Discovery of a New More Effective Anti-Cancer Treatment in Experimental Brain Tumor Models
"These data allows Oncolin to identify the potential clinical lead candidate for filing an IND with the FDA as soon as the preclinical studies will be completed," said Dr Donald Picker, COO of the company.
The founding scientists at MD Anderson have designed a drug that passes through the Blood Brain Barrier (BBB), a protective tissue which prevents most other drugs from entering the brain, where this drug is then retained in brain tumor cells selectively blocking the tumors metabolic machinery. This compound class also provides higher drug uptake and a longer drug half life. This drug class can also be used to treat other cancers that depend on glycolysis for survival such as breast and pancreatic cancers. This technology is covered under Oncolin's recent exclusive option to license agreement from The University of Texas M.D. Anderson Cancer Center, the # 1 cancer treatment center in the United State according to U.S. News and World Report.
About Oncolin Therapeutics, Inc.
Headquartered in Houston, Texas, Oncolin Therapeutics, Inc. is a publicly traded biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies. Additional information about Oncolin can be found on the web at www.oncolinthera.com.
Safe Harbor Statement
This press release contains statements that may constitute forward-looking statements, including the company's ability to successfully acquire and develop technologies that are and may be acquired. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about Oncolin's future business and financial results, refer to Oncolin's Quarterly Reports on Form 10-QSB and Annual Report on Form 10-KSB and other reports, which are on file with the Securities and Exchange Commission. Oncolin undertakes no obligation to update any forward-looking statement that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.
Oncolin Therapeutics, Inc., Houston
J. Leonard Ivins, 832-426-7909
Posted: June 2008